The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
07-Jun-19
$NA
Target:
Grupo Electro Stocks
Acquiror:
Würth Group
Advised Apax Partners, a global investment firm, on the sale of Grupo Electro Stocks, a leading Spanish distributor of electrical materials, to the Electrical Wholesale business unit within the Würth Group, a global leader in the distribution of assembling and fastening materials
07-May-19
$244 million
Target:
FTTH network including 933,000 BU’s
Advising MasMovil, the fourth largest Spanish telecom operator, in the sale of part of its fibre-to-the-home (FTTH) network to an international infrastructure fund. The transaction perimeter includes 933,000 homes across 5 main Spanish cities
26-Apr-19
$200 million
Target:
Lion's Specialty Cheese division
Acquiror:
Saputo Inc.
Advised Lion, an Australian subsidiary of Kirin and one of Australasia’s leading food and beverage companies, on the sale of its Specialty Cheese division to Saputo, one of the top ten dairy processors in the world
22-Mar-19
$NA
Target:
Four Pillars Gin
Acquiror:
Lion Beer Australia
Advised Lion, an Australian subsidiary of Kirin, on its acquisition of a strategic stake in Four Pillars Gin, Australia’s leading craft gin distillery
28-Jan-19
$NA
Target:
The Laundress Inc.
Acquiror:
Unilever plc
Advised The Laundress Inc., a laundry and home cleaning products brand, on its sale to Unilever, a British-Dutch consumer goods company
19-Dec-18
$NA
Target:
Starpharma Holdings Limited, patented VivaGel BV® product
Acquiror:
ITF Pharma, US subsidiary of Italfarmaco S.p.A.
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
06-Dec-18
$165 million
Target:
Storz & Bickel GmbH, related entities and IP
Acquiror:
Canopy Growth Corporation
Advised Canopy Growth, a leading diversified cannabis company, on its acquisition of Storz & Bickel, a premium manufacturer of vaporization devices
26-Nov-18
$880 million
Target:
Restaurant Brands New Zealand Limited
Acquiror:
Finaccess Capital, S.A. de C.V.
Advised Finaccess Capital, an investment company with a strong presence in the casual dining and quick service restaurant sector, on its 75% partial takeover of Restaurant Brands New Zealand, a corporate franchisee specialising in managing multi-site branded food retail chains (with brands consisting of KFC, Pizza Hut, Taco Bell and Carl’s Jr.)
24-Oct-18
$41 million
Target:
TeePublic
Acquiror:
Redbubble
Advised Redbubble, a global online independent artist community and marketplace, on the acquisition of TeePublic, a similar online platform, and associated A$61 million equity raising
10-Sep-18
$100 million
Target:
Montserrat Day Hospital Group
Acquiror:
Primary Health Care
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
07-May-18
$7.1 billion
Target:
Frutarom
Acquiror:
International Flavors and Fragrances
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
26-Apr-18
$NA
Target:
IslaLink
Acquiror:
Fiera Infrastructure
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
27-Mar-18
$13.0 billion
Target:
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Acquiror:
GlaxoSmithKline plc
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
27-Mar-18
$1.6 billion
Target:
Yakult
Acquiror:
Danone
Advised Danone, a leading global food & beverage company, on renewing its strategic partnership with Yakult, a global leader in probiotic beverages, as well as the sale of part of its stake in Yakult
26-Mar-18
$NA
Target:
Remedy Kombucha
Acquiror:
Lion Dairy & Drinks
Advised Lion, an Australian subsidiary of Kirin, on its acquisition of a strategic stake in Remedy Kombucha, Australia’s leading producer and distributer of kombucha beverages
20-Feb-18
$107 million
Target:
Macpac Holdings
Acquiror:
Super Retail Group
Advised Super Retail Group on the acquisition of Macpac, the New Zealand-based outdoor adventure retailer
30-Nov-17
$NA
Target:
MorphoSys AG
Acquiror:
I-Mab
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
30-Nov-17
$NA
Target:
Grupo Sidecu
Acquiror:
Portobello Capital
Advised the shareholders of Grupo Sidecu, the leading concessional sport center operator in Spain, on its sale of a controlling stake to Portobello Capital, a local private equity fund
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
22-Feb-17
$533 million
Target:
Lion’s stake in Warrnambool Cheese and Butter Factory Company
Acquiror:
Saputo Inc.
Advised Lion (an Australian subsidiary of Kirin), on the sale of its strategic stake in Warrnambool Cheese and Butter Factory to Canadian-based Saputo, under its all cash takeover offer
24-Nov-16
$NA
Target:
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Rivopharm SA
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
23-Nov-16
$NA
Target:
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Acquiror:
Arrow Generiques SAS
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
14-Nov-16
$NA
Target:
Lion’s Australian Premium Wine Business – Fine Wine Partners
Acquiror:
Accolade Wines
Advised Lion, a leading Australasian food and beverage company wholly owned by Japanese conglomerate Kirin, on the sale of its Australian wine business Fine Wine Partners to Accolade Wines, a portfolio company of CHAMP Private Equity
03-Nov-16
$NA
Target:
Fragrance Resources Group
Acquiror:
International Flavors & Fragrances Inc.
Advised IFF, one of the world’s largest flavors and fragrances businesses, on the acquisition of Fragrance Resources Group, a family-owned fragrance company headquartered in Switzerland
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)